https://www.nxtpsychedelics.com/news/articles/psychedelics/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder/